Autosomal Dominant Polycystic Kidney Disease clinical trials at UCSF
2 research studies open to eligible people
A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON
open to eligible people ages 12-70
This international, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with ADPKD. Approximately 850 patients will be enrolled.
San Francisco, California and other locations
An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
open to eligible people ages 12 years and up
This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with chronic kidney disease (CKD) who previously participated in one of the qualifying clinical studies with bardoxolone methyl. Patients will remain in the study until bardoxolone methyl is available through commercial channels or until patient withdrawal, whichever is sooner.
San Francisco, California and other locations
Our lead scientists for Autosomal Dominant Polycystic Kidney Disease research studies include Meyeon Park, MD.
Last updated: